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Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in newborns
and infants. CHI is characterized by unregulated secretion of insulin from pancreatic b cells. Here, we
reported the case of a large-for-gestational-age, full-term newborn that suffered from CHI and developed
severe and persistent hypoglycemia at an early stage of life. The infant was nearly unresponsive to
medical treatment, which included continuous intravenous glucagon infusion, oral diazoxide, and
nifedipine. After medical treatment had failed, an 18-ﬂuoro L-3,4-dihydroxyphenylalanine positron
emission tomography scan of the patient showed a focal lesion at the neck of the pancreas. The patient
received subtotal pancreatectomy, and shortly after the procedure, the patient's blood sugar returned to
the normal range. The patient was conﬁrmed to have a novel heterozygous mutation at position
c.2475þ1G>A of the ABCC8 gene. This is the ﬁrst report of a focal form of CHI in a patient in Taiwan,
which had preoperatively been conﬁrmed using 18-ﬂuoro L-3,4-dihydroxyphenylalanine positron
emission tomography.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Congenital hyperinsulinism (CHI) is a genetic disorder with
clinical symptoms that can range from mild to severe hypoglyce-
mia. This disease is also the major cause of persistent hypoglycemia
among newborns and infants [1]. In the literature, nine genes have
been reported to be associated with CHI, with the most common
genetic causes of CHI beingmutations in either ABCC8 or KCNJ11 [2].
Both genes are located on chromosome 11p; they encode, respec-
tively, the sulfonylurea receptor 1 (SUR1) and Kir 6.2, both of which
are subunits of the adenosine triphosphate-sensitive potassiumacKay Children Hospital, 92,
ct, Taipei, Taiwan. Tel.: þ886
g).
lief Tzu Chi Foundation. Publishedchannel (KATP channel) found in the pancreatic b cells. Most pa-
tients with either an ABCC8 mutation or a KCNJ11 mutation have
been found to be unresponsive to diazoxide, which is the ﬁrst-line
treatment for CHI [3]. In the past, those who were unresponsive to
medical therapy needed to receive a near-total pancreatectomy in
order to treat their severe and refractory hypoglycemia. However,
remarkable progress has been made regarding the diagnosis of CHI,
which has included the use of molecular diagnostic approaches and
18-ﬂuoro L-3,4-dihydroxyphenylalanine positron emission to-
mography (18F-DOPA PET) scanning; these procedures help
distinguish between the focal and diffuse forms of CHI. The infor-
mation obtained from these aids in deciding an optimal manage-
ment strategy for a given patient and helps predict the outcome [4].
Additionally, the incidence rate of the focal form of CHI has been
reported to be higher in Asians, which makes such progress espe-
cially important for the treatment of Asian populations [5,6]. Here,
we report the case of a Taiwanese newborn with CHI who wasby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Fig. 1. (A) Transverse view of a maximum intensity projection 18F-DOPA PET image
that demonstrates a focal lesion at the neck of the pancreas (black arrow). (B) Trans-
verse view of the abdominal computed tomography þ PET that revealed a bright
enhancement near the neck of the pancreas (white arrow). 18F-DOPA PET ¼ 18-ﬂuoro
L-3,4-dihydroxyphenylalanine positron emission tomography; PET ¼ positron emis-
sion tomography.
Fig. 2. A white nodule (1  1 cm2) found at the neck of the pancreas during the
operation.
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ﬁrst report in the literature of this mutation. The 18F-DOPA PET scan
diagnosed the patient as having a focal disease and accurately
localized the lesion at the neck of the pancreas. The patient's blood
sugar returned to the normal range after subtotal pancreatectomy.
The patient, who is now being followed up at our outpatient
department, has been found to be euglycemic and is fulﬁlling
normal developmental milestones.
2. Case report
This case describes a Taiwanese male patient who was born to a
nondiabetic G1P1 mother at 38 weeks of gestational age by vaginal
delivery and had a birth weight of 3660 g (> 90th percentile); the
baby had Apgar scores of 9 and 10 at 1 minute and 5 minutes,
respectively. During hospitalization, hypoglycemia (37 mg/dL) was
detected on the 2nd day of life, and a high glucose infusion rate was
required to keep his blood glucose in the normal range. Despite
continuous intravenous glucose supplementation and oral feeding,
his blood sugar levels still ﬂuctuated from 21 mg/dL to 145 mg/dL.
Two episodes of seizure occurred during his 3rd day of life while the
patient was hypoglycemic (40 mg/dL and 37 mg/dL). At this point,
the patient was treated with intramuscular phenobarbital.
An endocrine survey during hypoglycemia (serum blood
glucose, 39 mg/dL) showed a normal thyroid hormone level (free
T4, 1.27 ng/dL), a normal growth hormone level (10.5 ng/mL), and
a normal cortisol level (11.75 mg/dL), and the patient's blood was
negative for ketones. However, an inappropriately elevated serum
insulin level of 29.9 mIU/mL (normal range, 3e16 mIU/mL), an
abnormal c-peptide level of 4.62 ng/mL (normal range, 1e1.5 ng/
mL), an abnormal ammonia level of 104 mg/dL (normal range,
19e60 mg/dL), and a high insulin/glucose ratio of 0.77 (> 0.4) were
noted. Treatment with diazoxide was tried on the 40th day of life,
and the drug was gradually increased over the following days
until the maximum allowable dose of 20 mg/kg/d was reached.
During this period, intermittent hypoglycemia episodes were still
noted, especially when we tried to taper off the intravenous
glucose infusion. Nifedipine, together with a continuous glucagon
infusion, was then started on the 52nd day of life, but again no
clinical improvement was observed. Since the patient was unre-
sponsive to all available medical treatments, surgical intervention
was then planned in order to treat the patient's refractory
hypoglycemia.
Prior to the operation, we arranged for an 18F-DOPA PET scan.
This resulted in the detection of a focal lesion at the neck of the
pancreas (Fig. 1). Based on this ﬁnding, the patient received a
subtotal pancreatectomy on the 83rd day of life, and during surgery
a nodule-like lesion of about 1 cm 1 cmwas identiﬁed at the neck
of the pancreas and removed; this nodule was compatible with the
lesion found on the PET scan (Fig. 2). After the operation, the pa-
tient's blood sugar level returned to the normal range, and wewere
able to successfully discontinue intravenous treatment of the pa-
tient on the 93rd day of life. The patient was then discharged on the
95th day of life and has been followed up at our outpatient
department; he is euglycemic and has reached his normal devel-
opmental milestones.
2.1. Detection of mutations in the ABCC8 gene
Genomic DNA was isolated from the buffy coat of the whole
blood of this patient using standard procedures. All exons and
intron/exon boundaries of the ABCC8 gene was ampliﬁed by gene-
speciﬁc primers. The PCR product was puriﬁed using the ExoSAP-IT
PCR cleanup reagent (USB). The amplicons used the ﬂuorescence-
labeledmethodwith an automatic sequencer (model 3730; AppliedBiosystems) to verify the nucleotide sequence (TaqDyeDeoxy
Terminator Cycle Sequencing kit). The variations were analyzed
using the reference sequences from GenBank (NM000525.3 and
NM000352.4).
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region for ABCC8 by sequencing (Table 1). We next used the splicing
tool Human Splicing Finder (HSF3.0), and this predicted that one
heterozygous variant, namely at position c.2475þ1G>A within the
intron between exons 19 and 20 of ABCC8 (rs772026262), would
most probably affect gene splicing. This is the ﬁrst report of this
mutation in the literature (Fig. 3). It is well known that DNA vari-
ations at the intron/exon boundaries often affect normal splicing of
mRNA, which in turn affects the protein sequence and thence gene
functionality.
2.2. Histological ﬁndings
Histological analysis of the pancreatic specimen showed a low-
grade endocrine tumor that was composed of nests of polygonal
cells with moderate to abundant eosinophilic cytoplasm (Fig. 4A).
The tumor cells showed extensive immunoreactivity with
antichromogranin-A antibody. Chromogranin-A is a secretory
protein commonly associated with many neuroendocrine tumors
(Fig. 4B).
3. Discussion
CHI is a glucose metabolism disorder that is characterized by
unregulated secretion of insulin and profound hypoglycemia; it is
the most common cause of persistent hypoglycemia in newborns
and infants. The diagnostic criteria for CHI includes a large birth
weight for gestational age, elevated glucose requirement (glucose
infusion rate >10 mg/kg/min), an inappropriate elevation of insulin
level, repression of blood ketone production, and an inappropriate
glycemic response to glucagon when the blood sugar level is lower
than 50 mg/dL [2]. Here, we reported the case of a male newbornTable 1
Result of the screening of ABCC8 using the splicing tool Human Splicing
Finder (HSF3.0), which predicted that the variant (rs772026262, bold) most
probably affected gene splicing.
SNP number Variation description
rs2301703 c.579þ14C>T
rs1799858 c.1947G>A (p.Lys649Lys)
rs10658068 c.2291þ238-243del (TTTTTCT)
rs140565310 c.2291þ283delA
rs1800851 c.2292-34T>C
rs1800852 c.2292 -36C>T
rs772026262 c.2475þ1G>A
rs3214159 c.2556þ192delC
rs2106865 c.2820 þ17A>G
rs757110 c.4105G>T (p.Ser1369Lys)
rs4148646 c.4608þ54C>G
rs41282912 c.4609-82G>A
rs1799731 c.4609-103delC
SNP: single nucleotide polymorphism.
Fig. 3. A heterozygous variation at position c.2475þ1G>A affecting the intron and
exon boundaries between exons 19 and 20 in the ABCC8 (rs772026262) is identiﬁed.
Fig. 4. (A) A pancreatic low-grade endocrine tumor was found, which was composed
of nests of polygonal cells (H&E 100). (B) The pancreatic low-grade endocrine tumor
showed chromogranin-A immunostaining (100). H&E ¼ hematoxylin and eosin.with CHI that presented with persistent hypoglycemia and was
refractory to all medical therapies. An 18F-DOPA PET scan was able
to detect a focal lesion at the neck of the pancreas, and the patient's
blood sugar returned to the normal range after subtotal pancrea-
tectomy. This was the ﬁrst focal form CHI patient to be conﬁrmed in
Taiwan using a preoperative 18F-DOPA PET scan. The patient was
later conﬁrmed to have a mutationwithin the ABCC8 gene, and this
is the ﬁrst report of this mutation in the literature.
It has been reported in the literature that CHI can be caused by
mutation in nine different genes, namely, ABCC8, KCNJ11, GCK,
GLUD1, HADH, UCP2, HNF4A, HNF1A, and SLC16A1 [2,7e12]. The
most common genetic causes of CHI are mutations that inactivate
one of two adjacent genes that are located on chromosome
11p15.1; these are ABCC8 and KCNJ11, which encode the SUR1 and
Kir6.2 protein, respectively. These together form the KATP channel
in pancreatic b cells [13]. Loss of KATP channel activity results in
membrane depolarization, which opens the voltage-gated cal-
cium channels and raises intracellular calcium concentrations.
This then brings about an excessive and unregulated secretion of
insulin even during hypoglycemia. Snider et al [3] conducted a
large series of genotypeephenotype correlations involving 417
CHI cases and demonstrated that 89% of the diazoxide-
unresponsive CHI carried mutations affecting the KATP channel.
Those patients who were unresponsive to diazoxide then received
surgery, and after surgery, they were further classiﬁed into groups
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channel mutations were mostly associated with diffuse CHI, while
the presence of a paternal monoallelic recessive mutation seemed
to predict focal CHI with high sensitivity and speciﬁcity. Our pa-
tient carried a heterozygous point mutation at a splicing site
within ABCC8, and the patient was also found to have a focal lesion
affecting the neck of the pancreas. These ﬁndings are consistent
with previous reports [3,14,15].
The most important recent advance in the management of
children with CHI over the past 2 decades has been the intro-
duction of 18F-DOPA PET scanning to differentiate focal CHI from
diffuse CHI. This advance is most important regarding Asians
because the incidence rate of the focal form of CHI appears to be
higher among Asian than among Caucasian children [6,16]. In
many cases, focal lesions are difﬁcult to identify during surgery
and also cannot be detected by conventional image approaches
such as computed tomography and magnetic resonance imaging;
this is because they are generated during the normal organo-
genesis of the pancreas. In contrast to the diffuse disease, in
which surgery is only palliative, children with focal CHI can be
cured by surgical resection of the lesion; thus, it is important in
this context that a preoperative 18F-DOPA PET scan is usually able
to accurately differentiate and localize such a lesion [17]. How-
ever, 18F-DOPA PET scanning does not necessarily show the exact
size of the lesion and repeated intraoperative biopsies may be
necessary; these help surgeons determine the extent of pancre-
atectomy required [16].
Some authors have recommended that the continued presence
of hypoglycemia after 5 days or more at the maximum dose of
diazoxide (15mg/kg/d) should be considered a treatment failure. At
this point, these children are potential surgical candidates and
should receive an 18F-DOPA PET scan, which will help the surgeon
establish a surgical plan [2]. In our patient, diazoxidewas started on
the 40th day of life, since this medicine can be used only after
obtaining approval from the Taiwan Food and Drug Administration.
The patient's parents preferred medical treatment to surgical
intervention, which is the reason for arranging the operation only
on the patient's 83rd day of life, which is 43 days after the diazoxide
treatment was started. It is possible now, with the aid of an 18F-
DOPA PET scan, to differentiate focal CHI from diffuse CHI and
accurately localize the focal lesion(s). We would advocate that 18F-
DOPA PET scanning is carried out earlier and that surgery to treat
diazoxide-unresponsive cases is also instigated as early as possible;
this will help prevent recurrent severe hypoglycemia and the
possibility of a subsequent neurological deﬁcit.
CHI is still a medical challenge for pediatric endocrinologists.
Early diagnosis and adequate management are very important in
order to prevent any subsequent neurological sequelae. An 18F-
DOPA PET scan is very helpful when trying to distinguish between
the focal and diffuse forms of CHI, and the scan can also help inaccurately localizing any lesion that is present. An 18F-DOPA PET
scan should be considered to be a very useful guide when surgery is
carried out on any CHI infant with medically uncontrollable disease.References
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